Skip to main content
Download PDF

Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy

BMC Cancer volume 21, Article number: 105 (2021) Cite this article

The Original Article was published on 15 January 2021

Correction to: BMC Cancer (2021) 21:72

https://doi.org/10.1186/s12885-020-07760-x

Following publication of the original article [1], the authors reported typesetting error in Figs. 3 and 4. Sections of the graphs were mistakenly omitted. The family name of Mihoko Sutoh Yoneyama was also incorrectly published. This has been amended in this correction article.

Fig. 3
figure 1

Antitumor effect of BNCT in murine MBT2 tumor-bearing mice. a-f Tumor growth curves from the following treatment groups: (a) untreated control (cold control, blue dashed line); (b) IF7C(10BPA)RR injection (cold IF7C(10BPA)RR, red dashed line); (c) IF7K(10BSH)RR injection (cold IF7K(10BSH)RR, black dashed line); (d) Neutron-irradiation (hot control, blue solid line); (e) IF7C(10BPA)RR-mediated BNCT (hot IF7C(10BPA)RR, red solid line); and (f) IF7K(10BSH)RR-mediated BNCT (hot IF7K(10BSH)RR, black solid line). Groups were intravenously injected, and tumors irradiated with epi/thermal neutrons 40 min after injection on day 1. g Tumor growth curve comparing groups analyzed in A-F. Results are expressed as means ± SD. *P < 0.05 (Holm–Sidak method). N.S.: no significant difference. h Body weight of indicated groups. Results are expressed as means ± SD. i Tumor weight of indicated groups at sacrifice. Results are expressed as violin plots with dot plots. Red bold lines indicate the median value, while red dashed lines indicate the interquartile range value (Mann–Whitney test) (j) Photograph of resected tumors from the injected right thighs. If a tumor completely shrank, whole right thighs were resected and labeled as “no tumor”

Full size image
Fig. 4
figure 2

Antitumor effect of BNCT in a human YTS-1 xenograft model. a-f Tumor growth curves from the following treatment groups: (a) untreated control (cold control, blue dashed line); (b) IF7C(10BPA)RR injection (cold IF7C(10BPA)RR, red dashed line); (c) IF7K(10BSH)RR injection (cold IF7K(10BSH)RR, black dashed line); (d) Neutron-irradiation (hot control, blue solid line); (e) IF7C(10BPA)RR-mediated BNCT (hot IF7C(10BPA)RR, red solid line); and (f) IF7K(10BSH)RR-mediated BNCT (hot IF7K (10BSH)RR, black solid line). Indicated samples were intravenously injected, and tumors irradiated with epi/thermal neutrons 40 min after injection on days 1 and 7. g Tumor growth curve summarizing groups shown in A-F. Results are expressed as means ± SD. *P < 0.05 (Holm–Sidak method). N.S.: no significant difference. h Body weight of indicated groups. Results are expressed as means ± SD. i Tumor weight of indicated groups at sacrifice. Results are expressed as violin plots with dot plots. Red bold lines indicate the median value, while red dashed lines indicate the interquartile range. *P < 0.05 (Mann–Whitney test). (j) (j) Photograph of resected tumors from injected right thighs. If a tumor completely shrank, whole right thighs were resected and labeled as “no tumor”

Full size image

The corrected Figs. 3 and 4 are given below. The original article [1] has been corrected.

Reference

  1. Yoneyama T, Hatakeyama S, Sutoh-Yoneyama M, et al. Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy. BMC Cancer. 2021;21:72 https://doi.org/10.1186/s12885-020-07760-x.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Tohru Yoneyama and Shingo Hatakeyama contributed equally to this work.

Authors and Affiliations

  1. Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, 036-8562, Japan

    Tohru Yoneyama

  2. Department of Urology, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki, 036-8562, Japan

    Tohru Yoneyama, Shingo Hatakeyama & Chikara Ohyama

  3. Department of Cancer Immunology and Cell Biology, Oyokyo Kidney Research Institute, 90 Kozawa Yamazaki, Hirosaki, 036-8243, Japan

    Mihoko Sutoh Yoneyama

  4. Peptide Institute Inc., 7-2-9 Saito-Asagi, Osaka, Ibaraki, 567-0085, Japan

    Taku Yoshiya, Tsuyoshi Uemura & Takehiro Ishizu

  5. Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science (KURNS), Kyoto University, 2-1010 Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan

    Minoru Suzuki

  6. Aomori Prefecture Quantum Science Center (QSC), 2-190 Omotedate, Obuchi, Rokkasho-mura, Kamikita-gun, 039-3212, Japan

    Shingo Hachinohe

  7. Faculty of Science and Technology, Hirosaki University Graduate School of Science and Technology, 1-Bunkyo-cho, Hirosaki, 036-8562, Japan

    Shintaro Ishiyama

  8. Department of Biological Chemistry, Human Health Sciences, Graduate School of Medicine, Kyoto University, 53 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Motohiro Nonaka

  9. Tumor Microenvironment and Cancer Immunology Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA, 92037, USA

    Michiko N. Fukuda

Authors
  1. Tohru Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shingo Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mihoko Sutoh Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taku Yoshiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tsuyoshi Uemura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takehiro Ishizu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Minoru Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shingo Hachinohe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shintaro Ishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Motohiro Nonaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Michiko N. Fukuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chikara Ohyama.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yoneyama, T., Hatakeyama, S., Sutoh Yoneyama, M. et al. Correction to: Tumor vasculature-targeted 10B delivery by an Annexin A1-binding peptide boosts effects of boron neutron capture therapy. BMC Cancer 21, 105 (2021). https://doi.org/10.1186/s12885-021-07815-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-021-07815-7

BMC Cancer

ISSN: 1471-2407

Contact us